Johnson & Johnson’s $2 Billion U.S. Manufacturing Push Amid 35.2% Volume Drop to 50th Trading Rank

Johnson & Johnson (JNJ) closed 0.49% lower on August 25, 2025, with a trading volume of $1.11 billion, down 35.2% from the previous day, ranking 50th in market activity. The company announced a $2 billion investment in a biopharmaceutical manufacturing facility in Holly Springs, North Carolina, over the next decade. This project, part of a broader $55 billion commitment to U.S. manufacturing and R&D through 2029, aims to expand production capacity for advanced medicines and create approximately 120 jobs. CEO Joaquin Duato emphasized the move as part of strengthening the company’s domestic footprint, aligning with recent legislative support for healthcare innovation.

The investment follows similar initiatives, including a $2 billion facility in Wilson, North Carolina, which will employ over 500 workers and generate 5,000 construction jobs. These efforts reflect J&J’s strategy to localize production amid potential tariff risks and global supply chain uncertainties. The company also plans to announce additional U.S. site expansions in coming months, reinforcing its position as a leader in pharmaceutical and MedTech innovation. The Holly Springs facility, leveraging state-of-the-art infrastructure, will support next-generation therapies for oncology, immunology, and neurological diseases.

Analysts note that J&J’s sustained capital allocation to U.S. operations underscores its long-term resilience in a sector facing regulatory and trade challenges. While the stock’s recent decline contrasts with its broader $55 billion commitment, the focus on domestic manufacturing aligns with investor sentiment favoring supply chain stability. The company’s extensive U.S. manufacturing network, already the largest in its industry, is expected to bolster operational efficiency and patient access to critical treatments.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to 2025 yielded a total return of 31.52% over 365 days, with a 1-day average return of 0.98%. The approach achieved a Sharpe ratio of 0.79, indicating favorable risk-adjusted performance. Daily returns ranged from -4.47% to 4.95%, highlighting the volatility inherent in short-term momentum trading.